Written Question · S7W-04063 · Session 7
What discussions it has had with Biogen to facilitate the resubmission of Skyclarys (omaveloxolone) to the Scottish Medicines Consortium fo…
The question
To ask the Scottish Government what discussions it has had with Biogen to facilitate the resubmission of Skyclarys (omaveloxolone) to the Scottish Medicines Consortium for consideration for use within NHS Scotland, and what specific action it has taken as a result.
The answer
The Chief Pharmaceutical Officer (CPO) and Scottish Government officials have met with representatives from Biogen to understand if the company has any intention to resubmit omaveloxolone (Skyclarys®) to the Scottish Medicines Consortium (SMC). Biogen has provided assurance that it remains open to further commercial discussions, to support routine access to omaveloxolone (Skyclarys®) in the NHS in Scotland. Notably however, the decision on whether to resubmit to the SMC, and the timing of that resubmission, is entirely one for Biogen to make.
In the Official Report
No contribution in the Official Report cites S7W-04063 by reference.